Amylyx's avexitide halves hypoglycemia episodes in phase 3 trial for post‑bariatric patients

Amylyx Pharmaceuticals reported that its GLP‑1 receptor antagonist avexitide significantly reduced dangerous blood‑sugar drops in a phase 3 study.

The double‑blind Lucidity trial enrolled 78 individuals with post‑bariatric hypoglycemia, a rare complication after gastric‑bypass surgery, and compared daily avexitide injections with placebo.

Patients receiving avexitide experienced roughly half the number of severe hypoglycemic events per week compared with those on placebo, cutting the average from about one episode to around half an episode.

The results address an unmet need, as no approved therapies currently exist for this condition, and Amylyx plans to seek regulatory approval based on the data.